ライフサイエンスコーパス: low-risk

1 igh risk), 24.7% (moderate risk), and 16.9% (low risk).

2 lnerable (high-risk) or addiction-resistant (low-risk).

3 oints, intermediate risk; zero to one point, low risk.

4 tively identified 63% and 34% of patients as low risk.

5 n early stage of liver fibrosis had a stable low risk.

6 the patients would be classified as being at low risk.

7 reducing unnecessary procedures in those at low risk.

8 hether APOE2 homozygotes have a particularly low risk.

9 cted in 36.5% of participants categorized as low risk.

10 e positive whereas all MT- malignancies were low-risk.

11 tality and the number of complications after low-risk (1 complication - Odds Ratio [OR] 3.34 [95% CI

12 hospital B vs. A/G) was 1.1 days both among "low risk" (1.1 = 3.4-2.3 days) and "high risk" (1.1 = 3.

13 verall, 4123 (73.9%) were classified as CSRS low risk, 1062 (19.0%) medium risk, and 396 (7.1%) high

14 fication, there were 28 patients (9.2%) with low-risk, 189 (62.4%) with intermediate-risk, and 86 (28

15 ormal patients at high risk (9 of 16) and at low risk (2 of 8) of developing HCQ toxicity also showed

16 al risk after these cut points were 0.2% for low-risk, 5.0% for medium-risk, and 18.1% for high-risk

17 exposed HCP, 1599 (47.1%) were classified as low-risk, 765 (22.5%) as moderate-risk, and 1031 (30.4%)

18 phic evidence of stones and urine profile is low risk, 80%-95% consider candidates with unilateral as

19 s the number of complications accrued (e.g.: low-risk-9.2% in patients with >=3 complications; high-r

20 the training set that identified patients as low-risk (99% sensitivity) and high-risk (75% PPV), and

21 Identifying low-risk acute heart failure patients safe for discharge

22 ath (HR 3.94; 95% CI 1.90-6.56), whereas the low-risk adenoma group (10,978 patients) did not have a

23 f CRC and related deaths among the high- and low-risk adenoma groups were compared with the no-adenom

24 For low-risk adenoma individuals, colorectal cancer incidenc

25 10; findings were categorized as no-adenoma, low-risk adenoma, or high-risk adenoma.

26 U.S. patients aged 50, 60, or 70 years with low-risk adenomas (LRAs) (1 to 2 small adenomas) or high

27 Low-risk adenomas were not associated with a significant

28 er risk after removal of high-risk adenomas, low-risk adenomas, and after negative colonoscopy for al

29 urrent surveillance guidelines for high- and low-risk adenomas.

30 howed no conditioning, 36% (n = 25) showed a low risk and only 5% (n = 3) were found to have a high r

31 re high performers; 11.1% of individuals had low-risk and 6.6% had high-risk adenomas removed at scre

32 n probabilities ranged from 4.7 to 10.7% for low-risk and high-risk contact types, respectively.

33 tablished models of corneal transplantation (low-risk and high-risk models), we show that Tregs deriv

34 ifficulties, by investigating causality in a low-risk and low-cost way.

35 was transplanted from a donor who carried a low-risk APOL1 genotype; this contradicts current models

36 mend discontinuation of routine deworming in low-risk areas, continuation of annual deworming in high

37 However, given the very low risk associated with propranolol, most clinicians ar

38 stratification of the patient into high and low risk based on the morphology and chronology of the r

39 ge, presence of carcinoma in situ, and prior low-risk bladder cancer.

40 Within risk groups, low-risk BSI incidence was 1.9% (16 of 834) with BSI inc

41 oel criteria, graded mild by SSI, and graded low risk by SGS.

42 hs directed towards lesions determined to be low risk (by a multidisciplinary team).

43 ay 2017, we identified 4120 RYGB and 1457 SG low-risk cases defined by absence of previous abdominal

44 fants, in addition to a comparison sample of low-risk children (N=22).

45 cross the clusters (six [2.3%] of 261 in the low-risk cluster, 32 [6.3%] of 509 in the moderate-risk

46 y cause or disabling stroke at 1 year in the low-risk cohorts was 62, which is substantially lower th

47 bat the outbreak in the community by housing low-risk COVID-19 patients from April to August 2020.

48 Using the low-risk cut-off, the model identifies bacteremia with 9

49 +R- were reduced from 18.5% to 2.9%, whereas low-risk D-R- were increased from 13.5% to 24%.

50 toring excess triglycerides in metabolically low-risk depots.

51 ients with relapse after initial therapy for low-risk disease (R1/R2) was 50 +/- 13% compared with 21

52 disease (that requires early treatment) from low-risk disease (that could be managed using watchful w

53 All patients, except those with low-risk disease, received cranial irradiation.

54 th the potential to prevent overtreatment in low-risk disease.

55 t and hypofractionation in patients with non-low-risk ductal carcinoma in situ following breast-conse

56 8 years or older with completely excised non-low-risk ductal carcinoma in situ were randomly assigned

57 suppressor p53, potential substrates of the low-risk E6-E6AP complex remain largely elusive.

58 have become standard of care for women with low-risk, early-stage disease.

59 ld-caught stickleback from high- compared to low-risk environments due to genetic variation in plasti

60 us antibiotics were administered in 21.1% of low-risk episodes at presentation and at 7 days postpres

61 g risk enabling the ability to stratify into low-risk (EROA <20 mm(2) and RegVol <30 ml), intermediat

62 and 13 had a history of high-, moderate- or low-risk exposure (4.5%, 0.9%, and 0.8% of all high-, mo

63 0.9%, and 0.8% of all high-, moderate-, and low-risk exposures, respectively).

64 mucosal esophageal adenocarcinoma (T1b) with low-risk features (<500-mum invasion in the submucosa [s

65 s while reducing referrals for patients with low-risk features.

66 hs-cTnT identifies patients with a similar, low risk for ASCVD as those with a CAC score of zero.

67 imaging study of infants at familial high or low risk for ASD, parent-reported sleep onset problems w

68 m (CAC) scores of zero are associated with a low risk for atherosclerotic cardiovascular disease (ASC

69 iour for face stimuli in infants at high and low risk for autism from the British Autism Sibling Infa

70 .7% Black, 21.3% Other ethnicity) at high or low risk for bipolar spectrum disorder (BSD).

71 (41.0%) as intermediate, and 2447 (48.8%) as low risk for bleeding.

72 findings to a young adult sample at high or low risk for BSD.

73 ally marry at high rates and have relatively low risk for divorce.

74 ts (aged 18-50 years) who were considered at low risk for HIV infection and had not received any vacc

75 ted individuals aged 20-40 years who were at low risk for HIV infection and in good health.

76 nitial CVR <= 1.4 identifies fetuses at very low risk for hydrops, and a maximum CVR < 0.9 is associa

77 that are either not allergic in nature, are low risk for immediate hypersensitivity, or are a potent

78 r testing is rarely indicated in patients at low risk for major adverse cardiovascular events.

79 ould result in a patient being considered at low risk for metachronous advanced neoplasia, resulting

80 ation of expression should contribute to the low risk for progression of PTMC.

81 milliliter identified a group of patients at low risk for pulmonary embolism during follow-up.

82 72; 95% CI, 0.67-0.85) was associated with a low risk for respiratory symptoms at birth.

83 s MI, metabolic surgery is associated with a low risk for serious complications, lower risk of major

84 fter aortic valve replacement in patients at low risk for surgery.

85 it preferable for testing U.S.-born PLWH at low risk for TB exposure and with high CD4+ counts.

86 hsTnT did not identify patients at low risk for the primary outcome of rehospitalization, e

87 18-65 years), who were HIV-uninfected and at low-risk for HIV, were randomly assigned (3:1) to long-a

88 In a low-risk general population without known cardiovascular

89 pared with those of intermediate or low/very low-risk GISTs.

90 or SUV(max) was able to discriminate between low-risk Gleason score profiles and intermediate risk Gl

91 isk models), we show that Tregs derived from low-risk graft recipients have a superior capacity in pr

92 In terms of SB, "low-risk" grafts appeared appropriate for most severe pa

93 The BASIS cohort includes a low risk group and three high-risk groups who at age 3 w

94 ity, whereas patients predicted to be in the low risk group had a higher probability of survival.

95 otic core prevalence (30%), as compared with low-risk group (0.94+/-0.09 mm and 17%, respectively).

96 mes the occurrence rate of bacteremia in the low-risk group (27.4% vs 0.9%; p < 0.001).

97 ad a mortality rate 60 times higher than the low-risk group (28.2% vs 0.4%; p < 0.001).

98 es compared with one fungemic culture in the low-risk group (5.0% vs 0.02%; p < 0.001).

99 showed significantly worse survival than the low-risk group (P = 0.001), with a HR of 2.23 (1.37-3.65

100 nguished a high-risk group (score >2) from a low-risk group (score <=2) with 1-year survival of 8.3%

101 ts were 22 +/- 10 ng/mg of creatinine in the low-risk group and 55 +/- 11 ng/mg of creatinine in the

102 ents who improved to or were maintained in a low-risk group had a 1-year mortality <5%.

103 5-year disease-free survival in the HER2DX low-risk group was 93.5% (89.0-98.3%) and in the high-ri

104 group with a median TTP of 4.8 years, and a low-risk group with a median TTP of 9.3 years.

105 creening and interventions (if they are in a low-risk group).

106 ors and duodenal cancer were assigned to the low-risk group, and the others to the high-risk group.

107 7% for the high-, the intermediate-, and the low-risk group, respectively (P < .0001).

108 he high-risk group, and in no patient in the low-risk group.

109 % CI 84.0-93.8) and 96.2% (93.2-99.2) in the low-risk group; 65.0% (58.2-71.8) and 79.2% (73.4-85.0)

110 juvant treatment by avoiding therapy in very low risk groups and identifying patients who would benef

111 and MELD >=40 high-risk groups compared with low-risk groups in the derivation group (P < 0.001).

112 es that were facility-based or restricted to low-risk groups of women.

113 re stratified patients into high-risk versus low-risk groups with 2-y PFS rates of 59.1% versus 89.4%

114 rmediate- and high-risk groups compared with low-risk groups, with HRs at 10 years in the high-risk g

115 h biomarker median as a cutoff for high- and low-risk groups.

116 fied cluster 1 as high-risk and cluster 3 as low-risk groups.

117 y staff, who applied a uniform definition of low-risk guidelines that was aligned across sites.

118 future substance use problems, half were at low risk, half were at high risk.

119 region of SLC26A9-bearing variants from the low-risk haplotype generated 12%-20% higher levels of ex

120 The HCMR population has characteristics of low-risk HCM.

121 identification of false-positive results in low-risk health care workers.

122 family mental health history, we identified low-risk healthy (n = 2100), high-risk healthy (n = 2023

123 various a priori hypotheses differing in how low-risk healthy, high-risk healthy, remitted depressed

124 Low-risk histories include patients having isolated nona

125 ytoprotective function of Tregs derived from low-risk hosts occurs independently of direct cell-cell

126 High-risk but not low-risk HPV E7 target PTPN14 for proteolytic degradatio

127 tified ~190 potential substrate proteins for low-risk HPV-11 E6 and high-risk HPV-16 E6.

128 usally associated with malignant tumors, and low-risk HPVs such as HPV-11, which cause the developmen

129 of patient selection and index test bias but low risk in other domains.

130 procedure and, therefore, see high value and low risk in recommending prophylaxis.

131 ng intervals were unnecessarily frequent for low-risk individuals and insufficiently frequent for int

132 r LTBI patients), high-risk populations, and low-risk individuals based on recent publications.

133 (but no younger than two years old) and all low-risk individuals older than a given age, while maint

134 actor for osteoporotic fracture-can identify low-risk individuals who can safely be excluded from a f

135 d with BMI could not separate high-risk from low-risk individuals within underweight (BMI < 18.5 kg/m

136 , we model offering vaccination to all those low-risk individuals younger than a given age (but no yo

137 isk for ASD and 31 were typically developing low-risk infants.

138 als may consider using fewer precautions for low-risk interactions and more for high-risk interaction

139 Women >= 50 years of age with low-risk invasive breast carcinoma (pT1-2 pN0) were rand

140 t3+ progenitors from blood of both high- and low-risk LCH patients gave rise to DCs and LC-like cells

141 In both high- and low-risk LCH patients, CD34+c-Kit+Flt3+ progenitor frequ

142 therefore hypothesize that in both high- and low-risk LCH, the driver mutation is present in a BM-res

143 rate of corrosion for steel bars within the low risk limits.

144 predicted high risk compared to a predicted low risk location was 10.2 (95% CI 4.2-22.8).

145 ial, we randomly assigned patients with very-low-risk, low-risk, or intermediate-risk myelodysplastic

146 atheter Valves] 3) or noninferiority (Evolut Low Risk [LR]) of TAVR as compared with SAVR at 1- and 2

147 e siblings diagnosed with ASDs; whereas the 'low risk' (LR) group includes children without an ASD di

148 se smaller than 2 mm in diameter were deemed low risk (lrTS) for vision loss and those larger than 2

149 ardiac Risk Index, identify individuals with low risk (<1%) and higher risk (>=1%) for perioperative

150 year distant metastasis-free survival of the low-risk, medium-risk, and high-risk populations were 98

151 multipotent hematopoietic progenitor, while low-risk, MS-RO- and single-system LCH would result from

152 did not develop ASD (N=234), and infants at low risk (N=127).

153 able patients were included in the analysis: low-risk (n=222), intermediate-risk (n=227), high-risk (

154 Patients with low-risk NCCN-IPI had favorable survival outcomes with l

155 overtreatment, elderly individuals at truly low risk need to be identified.

156 entified 3 distinct cytogenetic risk groups: low risk (no MYC aberration), intermediate risk (MYC abe

157 DR was graded by standard methods as either low risk (no or mild DR) or high risk (moderate or sever

158 ty of this document is the fact that in some low-risk nonimmediate reactions ST are not mandatory, es

159 nly 1 or 2 small adenomas at baseline have a low risk of advanced neoplasia over 10 years.

160 tor but that have high analgesic potency and low risk of adverse effects, particularly no abuse liabi

161 with lower dropout, even in studies rated at low risk of attrition bias.

162 t asymptomatic prosthetic joints have a very low risk of being infected, and additional diagnostic wo

163 31 observational studies and no RCTs were at low risk of bias according to Cochrane's Risk of Bias to

164 No studies were at low risk of bias across all bias categories.

165 No study scored low risk of bias for all QUADAS-2 domains (patient selec

166 20 studies were assessed as being at low risk of bias for both random sequence generation and

167 Eight studies were at low risk of bias for the summary assessment of glycemic

168 No study was considered to have low risk of bias in all categories.

169 No study had a low risk of bias or assessed potential adverse bundle ef

170 Low risk of bias randomized trials which compared hypoth

171 No studies had low risk of bias, publication bias is likely, and studie

172 Four trials were judged as low risk of bias, three were unclear risk, and one was r

173 All trials were assessed as having low risk of bias.

174 nalysis, but only 13 of these trials were at low risk of bias.

175 on of decision rules to identify patients at low risk of bleeding complications, in whom long-term an

176 ticoagulation, an antiphospholipid antibody, low risk of bleeding, and patient preference favor indef

177 ofemoral obstruction, severe symptoms, and a low risk of bleeding.

178 egative risk factor, identifying patients at low risk of both CVD and non-CVD mortality.

179 h recent large studies showing exceptionally low risk of cancer associated with simple adnexal cysts.

180 PCSK9 variation was causally associated with low risk of cardiovascular mortality, but not with low a

181 study sought (1) to identify HF patients at low risk of cognitive impairment (obviating screening) a

182 ocardiography imaging of the appendage; with low risk of complications.

183 lows to determine a group of patients with a low risk of CRC detection that requires no further evalu

184 it may allow clinicians to offer patients at low risk of dementia earlier reassurance and relieve pre

185 at-risk individuals to those individuals at low risk of developing complications following infection

186 tion of non-metastatic patients into high or low risk of disease specific death, our decision tree mo

187 entified acute heart failure patients with a low risk of events.

188 Appropriate patient selection and low risk of fetal demise with FAV are critical factors f

189 ng driven tool to identify women at high and low risk of GDM.

190 ed conditions, we conclude that there may be low risk of growth of chemoorganotrophic bacteria typica

191 rs may help to identify patients with a very low risk of HCC development after SVR.

192 irrhosis before treatment (n = 38,351) had a low risk of HCC, except for those with pre-SVR FIB-4 sco

193 d good cholesterol that is associated with a low risk of heart disease, depends on their composition,

194 sessment and vital sign measurements, and at low risk of HIV infection in the opinion of study staff,

195 lthy volunteers aged 18-50 years who were at low risk of HIV infection.

196 rcutaneous coronary intervention (PCI), with low risk of immediate complications, or coronary artery

197 proved oral direct thrombin inhibitor with a low risk of intracerebral hemorrhage, ameliorates AD pat

198 and likely safe in selected patients at very low risk of liver injury from acetaminophen overdose.

199 sting is rarely indicated in patients with a low risk of major adverse cardiovascular events, but may

200 d as clustered microcysts demonstrate a very low risk of malignancy and can be classified as benign.

201 Lack of pain identifies patients at low risk of metastasis with sensitivity = 0.94 and negat

202 nary score stratified patients into high and low risk of poor outcome (P < .001).

203 hromboelastometry, to screen out patients at low risk of postoperative bleeding and then guide indivi

204 atify TLE patients into those at high versus low risk of presurgical or postsurgical memory deficits.

205 ic test for identifying TNBC patients with a low risk of recurrence.

206 threshold for identifying patients with very low risk of relapse in the training set provided 100% sp

207 rotection against further infection, and had low risk of reversion to pathogenic phenotypes.

208 healthy young adults, who are at relatively low risk of serious disease following natural infection,

209 Pacific-Northwest region is associated with low risks of regime shifts, indicating persistence contr

210 an identify a high percentage of patients at low-risk of 1-year mortality and, when used in conjuncti

211 For instance, a woman at an institution with low-risk of performing cALND would have 74% reduced odds

212 of 405 women at high-risk, and 214 women at low-risk of sPTB.

213 Patients were recategorized into low risk (one of 79, 1.3%), intermediate risk (19 of 79,

214 ging, possibly due to better exploitation of low-risk opportunities in high-risk environments.

215 known HPV genotypes and are not accurate for low-risk or mixed HPV genotypes.

216 ndomly assigned patients with very-low-risk, low-risk, or intermediate-risk myelodysplastic syndromes

217 nts aged 18 years or older with HPV-positive low-risk oropharyngeal cancer (non-smokers or lifetime s

218 possible in theory for an individual to be a low-risk outlier in all conditions simultaneously.

219 intravesical chemotherapy is recommended for low-risk papillary NMIBC, and induction intravesical che

220 m the 10th and 90th percentile limits in 253 low-risk participants free of cardiovascular disease or

221 cal cases can be reliably distinguished from low-risk participants using big-data spatial navigation

222 ut Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283).

223 s was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists

224 2.4-15.2) in high-risk patients compared to low-risk patients (p < 0.001).

225 their outcomes were compared with those for low-risk patients and for patients who met the Kidney Di

226 e identified within 2 hours of ED arrival in low-risk patients and within 6 hours in medium- and high

227 Most low-risk patients can be cured without adjuvant therapy,

228 bias due to physicians selecting relatively low-risk patients for lumbar puncture.

229 Low-risk patients had a 2.7% acute care rate.

230 ecision concerning TAVR versus SAVR in older low-risk patients on the basis of current evidence suppo

231 No CTCs (CTC-negative) were detected in the low-risk patients or benign disease.

232 Low-risk patients received three cycles without CNS prop

233 durability on life expectancy in a cohort of low-risk patients similar to those in recent trials.

234 This is the first presentation on 8,395 low-risk patients treated in 2019.

235 Model discrimination was good in high- and low-risk patients undergoing standard once-weekly evalua

236 Even if low-risk patients were younger compared with the other g

237 This model could increase identification of low-risk patients who can be safely discharged from the

238 mic cardiomyopathy, particularly to identify low-risk patients who may not benefit from prophylactic

239 elect young patients aged 30-49 years and in low-risk patients with a family history.

240 of the SAPIEN 3 Transcatheter Heart Valve in Low-Risk Patients With Aortic Stenosis) CT substudy rand

241 in improving classification of high- versus low-risk patients with HCC for DDLT.

242 med to compare echocardiographic findings in low-risk patients with severe aortic stenosis after surg

243 th status outcomes of TAVR versus surgery in low-risk patients with severe AS.

244 scatheter aortic valve replacement (TAVR) to low-risk patients with symptomatic severe aortic stenosi

245 Among low-risk patients, a higher proportion of the interventi

246 boelastometry screening effectively excluded low-risk patients, in that none in the cohort arm (FibTE

247 In younger and low-risk patients, TAVI had an early safety benefit over

248 alysis of RCTs comparing TAVR versus SAVR in low-risk patients, TAVR was associated with significantl

249 Compared to low-risk patients, there was a graded increase in risk o

250 However, in younger low-risk patients, valve durability must be weighed agai

251 sions and/or Mo and DCs in blood of multiple low-risk patients.

252 TAVR now extends from extreme- to low-risk patients.

253 1-2 was identified as the cutoff to identify low-risk patients; and the score that distinguished quar

254 althy aging laboratory cohort into high- vs. low-risk persons based on their genetic (APOE) and demog

255 The specificity in the low-risk population was slightly lower for QFT-Plus than

256 Oseltamivir decreased viral shedding in this low-risk population.

257 ity of sudden cardiac deaths (SCDs) occur in low-risk populations often as the first manifestation of

258 The prevalence among low-risk populations was 6% (CI, 4% to 8%; P for interac

259 ectrum of operative risk, from inoperable to low-risk populations, in properly designed, randomized c

260 ent associations with SCD risk in apparently low-risk populations.

261 tal morbidities and cost-related outcomes in low-risk pregnancies.

262 S were 2.3 and 3.4 days respectively, among "low risk" pregnancies.

263 resence of TP53, RB1, or KDM6A mutation) and low-risk (presence of ARID1A, FGFR3, PIK3CA, STAG2, and/

264 hus deploying increased surveillance or even low-risk preventive therapies should these be available)

265 The inclusion of elder age-groups to the low-risk programme typically lessened the cost-effective

266 an and non-Hispanic White men diagnosed with low-risk prostate cancer between January 1, 2001, and De

267 this retrospective cohort study of men with low-risk prostate cancer followed up for a median of 7.6

268 nd, to develop indicators to better stratify low-risk prostate cancer for determining which men shoul

269 re is concern that African American men with low-risk prostate cancer may harbor more aggressive dise

270 icts adverse pathology (AP) in patients with low-risk prostate cancer treated with immediate surgery.

271 In low-risk PTLD, outcomes were similar between therapies.

272 oral anticoagulation enrolled in the Evolut Low Risk randomized trial underwent computed tomographic

273 statement of heroin-seeking in high- but not low-risk rats, again with no effect on motivation.

274 statement of heroin-seeking in high- but not low-risk rats.

275 ve relapse > 1 year after initial diagnosis (low risk) received vinblastine monotherapy.

276 ion of stage III colon cancer into high- and low-risk recurrence groups, and poor and good prognosis

277 ) provided a hazard ratio (HR) for high- vs. low-risk recurrence of 8.976 (95% confidence interval (C

278 s without malignancy and among patients with low-risk SAB.

279 Compared with low-risk score group, high-risk group had 7-fold increas

280 0% had intermediate risk scores, and 20% had low risk scores.

281 A low-risk strategy of diverting flights only if there is

282 Here, we report on the low-risk stratum of the trial.

283 ly assessed coronary plaque progression in a low-risk study population during long-term follow-up.

284 nded screening strategies for IGHG high- and low-risk survivors is needed, including careful reconsid

285 5,000 per QALY gained for all strategies for low-risk survivors, representing approximately 40% of th

286 ventricular dysfunction and HF screening in low-risk survivors.

287 ers more than personal contacts, and testing low-risk symptomatic individuals before high-risk sympto

288 ect thrombocytopenia and coagulopathy before low-risk therapeutic paracentesis, thoracentesis, and ro

289 stratification tool, we identified high- and low-risk threshold points.

290 -fraction stereotactic body radiotherapy for low-risk to intermediate-risk localised prostate cancer.

291 er genetic correlations in high-risk than in low-risk treatments.

292 higher mutational load in high-risk than in low-risk tumors.

293 In general, the addition of low-risk vaccination programmes whose coverage encompass

294 ts with precursor B-cell ALL (B-ALL) at very low risk (VLR) of relapse and treated them with a reduce

295 Compared to low risk volunteers, those at elevated risk had lower [(

296 -95.0), and 73.9% (66.0-82.7), respectively (low-risk vs high-risk hazard ratio [HR] 0.04, 95% CI 0.0

297 1.4-5.6, p=0.0040) and as group categories (low-risk vs high-risk HR 0.27, 0.1-0.7, p=0.005).

298 t presentation identified 45% of patients at low risk with a negative predictive value (NPV) of 100%

299 V infection rates than those deemed to be at low risk with both preemptive (73.3% vs 44.4%; odds rati

300 Nulliparous low-risk women with singletons were included.